Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the ...

Camurus and Lilly have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Medical Devices & Diagnostics Analysts, along with Dr. Jolie Chang, Chief of Sleep Surgery Division at UCSF, discuss 2Q25 sleep medicine trends ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE: LLY) entered into a collaboration and license agreement.